🇺🇸 FDA
Pipeline program

TAK-771

TAK-771-3002

Phase 3 small_molecule active

Quick answer

TAK-771 for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials